FDA Approved: VABYSMO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for VABYSMO (faricimab) submitted by Genentech, Inc., indicating an update to the product labeling or indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

SUPPL AP for VABYSMO (FARICIMAB)